Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide,
about
Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide,
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Clinical effectiveness and cos ...... fludarabine, cyclophosphamide,
@ast
Clinical effectiveness and cos ...... fludarabine, cyclophosphamide,
@en
Clinical effectiveness and cos ...... fludarabine, cyclophosphamide,
@en-gb
type
label
Clinical effectiveness and cos ...... fludarabine, cyclophosphamide,
@ast
Clinical effectiveness and cos ...... fludarabine, cyclophosphamide,
@en
Clinical effectiveness and cos ...... fludarabine, cyclophosphamide,
@en-gb
prefLabel
Clinical effectiveness and cos ...... fludarabine, cyclophosphamide,
@ast
Clinical effectiveness and cos ...... fludarabine, cyclophosphamide,
@en
Clinical effectiveness and cos ...... fludarabine, cyclophosphamide,
@en-gb
P2093
P356
P1154
2-s2.0-85021268311
P1476
Clinical effectiveness and cos ...... fludarabine, cyclophosphamide,
@en
P2093
Abraham Varghese
Alexandra Smith
Alison Smith
Andy C Rawstron
Anna Chalmers
Dena R Howard
John L O'Dwyer
Lucy McParland
Roberta Longo
Talha Munir
P356
10.3310/HTA21280
P5530
P577
2017-05-01T00:00:00Z
P6179
1086129997